Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 16/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933403 | 0.84 | F2RL3 (0.44) | F2RL3F2ALOX5 | |
| SCHEMBL15349009 | 0.82 | F2RL3 (0.36) | F2RL3ALOX5CNR1CNR2 | |
| SCHEMBL15349111 | 0.70 | F2RL3 (0.42) | F2RL3F2ALOX5CNR1CNR2 | |
| SCHEMBL15349023 | 0.70 | F2RL3 (0.41) | F2RL3F2ALOX5CNR1CNR2 | |
| SCHEMBL24035816 | 0.69 | L3MBTL1 (0.40) | CNR1CNR2 | |
| SCHEMBL15348862 | 0.69 | ALOX5 (0.42) | F2RL3F2ALOX5CNR1CNR2 | |
| SCHEMBL23901916 | 0.67 | — | — | |
| SCHEMBL15349260 | 0.65 | F2RL3 (0.36) | F2RL3CNR1CNR2 | |
| SCHEMBL15349162 | 0.65 | ALOX5 (0.40) | F2RL3F2ALOX5CNR1CNR2 | |
| SCHEMBL21962502 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | F2RL3 1/4885F2 13/4885ALOX5 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.